[HTML][HTML] Recent therapeutic trends and promising targets in triple negative breast cancer

SY Hwang, S Park, Y Kwon - Pharmacology & therapeutics, 2019 - Elsevier
Breast cancer accounts for 25% of all types of cancer in women, and triple negative breast
cancer (TNBC) comprises around 15~ 20% of breast cancers. Conventional chemotherapy …

Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018

JM Loree, S Anand, A Dasari, JM Unger… - JAMA …, 2019 - jamanetwork.com
Importance Representative racial/ethnic participation in research, especially in clinical trials
that establish standards of care, is necessary to minimize disparities in outcomes and to …

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines

J Dutil, Z Chen, AN Monteiro, JK Teer, SA Eschrich - Cancer research, 2019 - AACR
Recent work points to a lack of diversity in genomics studies from genome-wide association
studies to somatic (tumor) genome analyses. Yet, population-specific genetic variation has …

Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women

T O'Meara, A Safonov, D Casadevall, T Qing… - Breast cancer research …, 2019 - Springer
Abstract Purpose African-American (AA) patients with triple-negative breast cancer (TNBC)
are less likely to achieve pathologic complete response from neoadjuvant chemotherapy …

Atypical Chemokine Receptor 1 (DARC/ACKR1) in Breast Tumors Is Associated with Survival, Circulating Chemokines, Tumor-Infiltrating Immune Cells, and African …

BD Jenkins, RN Martini, R Hire, A Brown… - … , biomarkers & prevention, 2019 - AACR
Background: Tumor-specific immune response is an important aspect of disease prognosis
and ultimately impacts treatment decisions for innovative immunotherapies. The atypical …

Dancing from bottoms up–roles of the POZ-ZF transcription factor Kaiso in cancer

CC Pierre, SM Hercules, C Yates, JM Daniel - Biochimica et Biophysica …, 2019 - Elsevier
The POZ-ZF transcription factor Kaiso was discovered two decades ago as a binding partner
for p120 ctn. Since its discovery, roles for Kaiso in diverse biological processes (epithelial-to …

Disparities in breast cancer diagnosis for immigrant women in Ontario and BC: results from the CanIMPACT study

AK Lofters, ML McBride, D Li, M Whitehead… - BMC cancer, 2019 - Springer
Abstract Background In Canada, clinical practice guidelines recommend breast cancer
screening, but there are gaps in adherence to recommendations for screening, particularly …

[HTML][HTML] Reporting of race in genome and exome sequencing studies of cancer: a scoping review of the literature

A Nugent, KR Conatser, LL Turner, JT Nugent… - Genetics in …, 2019 - Elsevier
Purpose Minorities are often underrepresented in clinical cancer research yet the frequency
of reporting of race in genomic sequencing studies of cancer is unknown. This scoping …

The impact of molecular status on survival outcomes for invasive micropapillary carcinoma of the breast

GD Lewis, Y Xing, W Haque, T Patel… - The breast …, 2019 - Wiley Online Library
Invasive micropapillary carcinoma (IMPC) is an uncommon variant of breast cancer.
Previous studies demonstrated this subtype is often hormone receptor (HR)‐positive …

[HTML][HTML] Genomic analysis of racial differences in triple negative breast cancer

CS Chang, E Kitamura, J Johnson, R Bollag… - Genomics, 2019 - Elsevier
Triple negative breast cancer (TNBC) is more prevalent in African Americans (AAs), has a
more aggressive clinical course including a higher mortality rate and an increased …